Health Care • Medical/Dental Instruments
$12.83 ▲ +0.59
(+4.82%)
MKT CAP: $998.2M • VOL: 1.19M
52W L $9 52W H $20
IART // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.64B | $1.61B | $1.54B |
| YoY Revenue Growth % | +1.5% | +4.5% | — |
| Gross Profit | $831.6M | $882.1M | — |
| Gross Margin % | 50.9% | 54.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$493.4M | $28.4M | $111.5M |
| Operating Margin % | -30.2% | 1.8% | 7.2% |
| Net Income (GAAP) | -$516.8M | -$6.9M | $67.7M |
| EBITDA (Normalized) | -$428.2M | $111.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $50.4M | $129.4M | $140.0M |
| Capital Expenditures (CapEx) | $81.4M | $104.4M | — |
| Free Cash Flow (FCF) | -$31.1M | $25.0M | $140.0M |
| FCF Margin % | -1.9% | 1.6% | 9.1% |
| Return on Invested Capital (ROIC %) | -45.0% | 1.7% | — |
| Cash & Short-Term Equivalents | $235.0M | $246.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.04B | $1.55B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IART.